According to a study that among patients who have undergone allogeneic hematopoietic stem cell transplantation (HCT), biobehavioral symptoms, such as sleep disruption and fatigue interference, may signal an increased risk of relapse and mortality over 6 years after HCT.
 |
| Photo: Sleep Disruption Fatigue | InStyleHealth |
Research analysis involved 241 adults who received
allogeneic HCT for a hematologic malignancy. They completed self-report
measures of depression symptoms, sleep quality, and fatigue prior to HCT and 100
days following the procedure. The follow-up for clinical results lasted up to 6
years.
Utilizing the multivariable cox proportional hazard
models controlled for patient demographic and medical characteristics revealed
that the risk of mortality was independently correlated with high pre-HCT sleep
disruption and greater post-HCT fatigue interference.
On the other hand, moderate pre-HCT sleep disruption
came out as a risk factor for relapse.
The biobehavioral symptoms had no correlation with the
incidence of chronic graft-versus-host disease (cGVHD).
Results indicate that the identified predictors of a
heightened risk for 6-year relapse and mortality after HCT are responsive to treatment.
By itself, they offer specific targets for intervention to improve HCT results.
For complete details of the study, click here.
Source: J Natl Cancer Inst 2021;doi:10.1093/jnci/djab032